Effect of Wenjingtongluo prescription combined with acupuncture and moxibustion on ESR, Fib and hemorheology in patients with cervical spondylosis / 中国生化药物杂志

Objective To investigate effect of Wenjingtongluo prescription combined with acupuncture and moxibustion on ESR, Fib and hemorheology in patients with cervical spondylosis.Methods 110 cases of cervical spondylosis were divided into two groups, 55 cases in each group.The control group was treated with acupuncture and moxibustion.Experimental group on the basis of acupuncture treatment, were given Wenjingtongluo prescription.The PRI index, VAS score and blood rheology of the two groups were compared.Results The total effective rate of the experimental group was significantly higher than that of the control group (92.73% vs 76.36%) .There was a significant difference (χ2 =5.636, P <0.05) .After treatment, the two groups of PRI index ( emotional score, sensory score, total score ) , VAS score were significantly reduced ( P <0.05 ) .After treatment, the PRI index ( sensory score, total score) and VAS score of the experimental group were significantly lower than those of the control group after treatment.The difference was statistically significant(P<0.05).After treatment, two groups of ESR, Fib, PCV, whole blood viscosity, whole blood viscosity decreased significantly( P<0.05).The experimental group after treatment, ESR, Fib, PCV, whole blood viscosity, whole blood viscosity was significantly lower than the control group after treatment.The difference was statistically significant(P<0.05).Conclusion Wenjingtongluo prescription combined with acupuncture can significantly improve the clinical symptoms, reduce the pain of patients and improve the level of blood rheology.

Sustained efficacy of alpha-interferon therapy combined with Yixuesheng Capsule in treatment of chronic hepatitis B / 中国中药杂志

<p><b>OBJECTIVE</b>To observe the difference between the combination therapy of alpha-interferon (IFN-alpha) therapy Yixuesheng Capsule and the monotherapy of IFN-alpha in treatment of chronic hepatitis B.</p><p><b>METHOD</b>A total of 288 patients with HBeAg-positive chronic hepatitis B proven by liver biopsy were included in this study. During the individualized therapy, they received hypodermic injection of IFN-alpha 1b, with 5 MU x time(-1) and three times x w(-1). Of them, 125 patients received combination therapy with Yixuesheng Capsule for three months, with 1.0 g/time and three times/d; and 163 patients received only IFN-alpha 1b (the IFN-alpha monotherapy group). After the course of therapy, all patients were followed up for at least 24 months. The intention-to-treat analysis was adopted for statistic analysis.</p><p><b>RESULT</b>The two groups showed no statistical significance by gender, age, liver necroinflammation grading, liver fibrosis staging, serum ALT levels, serum HBV DNA levels and IFN-alpha therapy course. The whole course and the 24-month follow-up visit cover all of 112 patients in the combination treatment group and 141 cases in the IFN-alpha monotherapy group. The response rates of the combination treatment group and the IFN-alpha monotherapy group were 48.0% (60/125) and 35.0% (57/163) (x = 4.980, P = 0.026) at the end of treatment, respectively, 45.6% (57/125) and 33.1% (54/163) (x2 = 4.645, P =0.031) at the end of 12-month-follow-up period, respectively, and 38.4% (48/125) and 32.5% (53/163) (x2 = 1.076, P = 0.300) at the end of 24-month follow-up period, respectively.</p><p><b>CONCLUSION</b>The combination treatment with IFN-alpha and Yixuesheng Capsule shows a slightly better sustained efficacy on HBeAg-positive chronic hepatitis B patients compared with IFN-alpha monotherapy.</p>

A comparison of curative effect between Telbivudine and lamivudine in patients with chronic hepatitis B virus / 中国基层医药

Objective To analyze efficacy in patients with chronic hepatitis B virus by telbivudine or lamivu-dine. Methods To collect 100 cases of patients with chronic hepatitis B, according different drugs divided into: tel-bivudine group(50 cases)and 50 cases of lamivudine group. Methods The HBV-DNA baseline decline value、HBV DNA below the detection limit、treatment response、HBeAg negative rate、ALT normalization rote、virological response rates、primary treatment failure rate were observed. Results The treatment efficacy at 52 weeks in telbivudine group of HBV-DNA decline in the value of the baseline (6.21og10), HBV DNA below the detection limit (69.6%)、treat-ment response(64.2%), HBeAg negative conversion rate(30.5%)、ALT normalization rate (88.9%)、virologic re-sponse rates (30.5%), primary treatment failure rate(3.6%), higher than the larnivudine group(5.41 og10、43.4%、 86.8%、20.3%、75.1%、18.1%、16.0%) (t =3.65, t =6.55, t =3.95, t =3. 85, t =8.65,t =6.06, t =15.02,P <0.05～0.01). Conclusion The curative effect of telbivudine and lamivudine at 52 weeks achieve better efficacy; curative effect of telbivudine higher than the lamivudine.